

## Clinician Management Resource for *CHEK2*

This overview of clinical management guidelines is based on this patient's positive test result for a *CHEK2* gene mutation. Unless otherwise stated, medical management guidelines used here are limited to those issued by the National Comprehensive Cancer Network® (NCCN®)<sup>1,2</sup> in the U.S. Please consult the referenced guideline for complete details and further information.

Clinical correlation with the patient's past medical history, treatments, surgeries and family history may lead to changes in clinical management decisions; therefore, other management recommendations may be considered. Genetic testing results and medical society guidelines help inform medical management decisions but do not constitute formal recommendations. Discussions of medical management decisions and individualized treatment plans should be made in consultation between each patient and his or her healthcare provider, and may change over time.

SCREENING/SURGICAL CONSIDERATIONS	AGE TO START	FREQUENCY
<b>Female Breast Cancer</b>		
Breast Screening <sup>1</sup> <ul style="list-style-type: none"> <li>Mammography with consideration of tomosynthesis</li> <li>Consider breast MRI with contrast</li> </ul>	40 years old, or 5-10 years before the earliest known breast cancer in the family	Every 12 months
For consideration of risk-reducing mastectomy, manage based on family history	Individualized	N/A
<b>Colorectal Cancer<sup>2</sup></b>		
Colonoscopy <i>For patients with colorectal cancer, please refer to the surveillance recommendations for post-colorectal cancer resection in the NCCN Guidelines for Colon Cancer and Rectal Cancer.</i>	For probands unaffected by colorectal cancer with a first degree relative with colorectal cancer, 40 years old or 10 years prior to age of first degree relative's age at colorectal cancer diagnosis  For probands unaffected by colorectal cancer and no first degree relative with colorectal cancer, 40 years old	Every 5 years
<b>Prostate Cancer<sup>3</sup></b>		
No specific screening guidelines exist at this time	N/A	N/A

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. V1.2020. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed December 26, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal. V3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed December 26, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
3. Pritchard CC, *et al.* Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *N Engl J Med.* 2016 Aug 4; 375(5):443-53.